Steven Magnuson

3.8k total citations
23 papers, 1.5k citations indexed

About

Steven Magnuson is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Steven Magnuson has authored 23 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Organic Chemistry and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Steven Magnuson's work include Protein Degradation and Inhibitors (5 papers), Melanoma and MAPK Pathways (4 papers) and Synthesis and biological activity (2 papers). Steven Magnuson is often cited by papers focused on Protein Degradation and Inhibitors (5 papers), Melanoma and MAPK Pathways (4 papers) and Synthesis and biological activity (2 papers). Steven Magnuson collaborates with scholars based in United States, Canada and France. Steven Magnuson's co-authors include Benjamin P. Fauber, F. Anthony Romero, Mark Merchant, Derrick L. J. Clive, Vickie Tsui, Lingyan Jin, Karen E. Gascoigne, Terry D. Crawford, Ryan Raisner and Samir Kharbanda and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Cancer Research.

In The Last Decade

Steven Magnuson

23 papers receiving 1.5k citations

Peers

Steven Magnuson
Frank Bennett United States
Hariprasad Vankayalapati United States
Gary E. Schiltz United States
David M. Ryckman United States
Kiyohiro Nishikawa Japan
Edward H. Walker United Kingdom
Sun‐Young Han South Korea
Kanami Yamazaki Japan
Giovanni Di Maira Italy
Vered Klinghofer United States
Frank Bennett United States
Steven Magnuson
Citations per year, relative to Steven Magnuson Steven Magnuson (= 1×) peers Frank Bennett

Countries citing papers authored by Steven Magnuson

Since Specialization
Citations

This map shows the geographic impact of Steven Magnuson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Magnuson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Magnuson more than expected).

Fields of papers citing papers by Steven Magnuson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Magnuson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Magnuson. The network helps show where Steven Magnuson may publish in the future.

Co-authorship network of co-authors of Steven Magnuson

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Magnuson. A scholar is included among the top collaborators of Steven Magnuson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Magnuson. Steven Magnuson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Villemure, Elisia, Jack A. Terrett, Robin Larouche‐Gauthier, et al.. (2021). A Retrospective Look at the Impact of Binding Site Environment on the Optimization of TRPA1 Antagonists. ACS Medicinal Chemistry Letters. 12(8). 1230–1237. 10 indexed citations
2.
Katavolos, Paula, Gary Cain, Cindy Farman, et al.. (2020). Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs. Toxicologic Pathology. 48(3). 465–480. 8 indexed citations
3.
Nagata, Denise E. de Almeida, Eugene Y. Chiang, Suchit Jhunjhunwala, et al.. (2019). Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. Cell Reports. 27(1). 269–281.e4. 54 indexed citations
4.
Chernov-Rogan, Tania, Eleonora Gianti, Chang Liu, et al.. (2019). TRPA1 modulation by piperidine carboxamides suggests an evolutionarily conserved binding site and gating mechanism. Proceedings of the National Academy of Sciences. 116(51). 26008–26019. 18 indexed citations
5.
Raisner, Ryan, Samir Kharbanda, Lingyan Jin, et al.. (2018). Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. Cell Reports. 24(7). 1722–1729. 223 indexed citations
6.
Jin, Lingyan, Emily Chan, Ehud Segal, et al.. (2017). Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. Cancer Research. 77(20). 5564–5575. 105 indexed citations
7.
McGrath, John P., Kaylyn E. Williamson, Srividya Balasubramanian, et al.. (2016). Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes. Cancer Research. 76(7). 1975–1988. 70 indexed citations
8.
Burdick, Daniel J., Shumei Wang, Christopher E. Heise, et al.. (2015). Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(21). 4728–4732. 13 indexed citations
9.
Romero, F. Anthony, Alexander M. Taylor, Terry D. Crawford, et al.. (2015). Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. Journal of Medicinal Chemistry. 59(4). 1271–1298. 131 indexed citations
10.
Burch, Jason D., Steven Magnuson, Daniel F. Ortwine, et al.. (2014). Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors. Bioorganic & Medicinal Chemistry Letters. 24(11). 2448–2452. 13 indexed citations
11.
Wang, Lan, Mark Stanley, Jason Boggs, et al.. (2014). Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 24(18). 4546–4552. 19 indexed citations
12.
Fauber, Benjamin P. & Steven Magnuson. (2014). Modulators of the Nuclear Receptor Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc). Journal of Medicinal Chemistry. 57(14). 5871–5892. 123 indexed citations
13.
Lau, Ted, Emily Chan, Marinella Callow, et al.. (2013). A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth. Cancer Research. 73(10). 3132–3144. 256 indexed citations
14.
Wang, Xiaojing, Steven Magnuson, Huiyong Hu, et al.. (2013). Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design. Bioorganic & Medicinal Chemistry Letters. 23(11). 3149–3153. 55 indexed citations
15.
René, Olivier, et al.. (2012). Efficient syntheses of 2-fluoroalkylbenzimidazoles and -benzothiazoles. Tetrahedron Letters. 54(3). 201–204. 28 indexed citations
16.
Tsui, Vickie, Paul Gibbons, Mark Ultsch, et al.. (2010). A new regulatory switch in a JAK protein kinase. Proteins Structure Function and Bioinformatics. 79(2). 393–401. 20 indexed citations
17.
Balzano, Laura, et al.. (2007). An OMICs Approach for Assessing the Safety of Single-Walled Carbon Nanotubes in Human Skin and Lung Cells. TechConnect Briefs. 2(2007). 651–654. 2 indexed citations
18.
Lowe, Derek, Steven Magnuson, James H. Cook, et al.. (2004). In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipase. Bioorganic & Medicinal Chemistry Letters. 14(12). 3155–3159. 56 indexed citations
19.
Bullock, William H., et al.. (2002). Prospects for Kinase Activity Modulators in the Treatment of Diabetes and Diabetic Complications. Current Topics in Medicinal Chemistry. 2(9). 915–938. 18 indexed citations
20.
Clive, Derrick L. J. & Steven Magnuson. (1995). Synthesis of the sesquiterpene (±)-ceratopicanol: Use of radicals derived from epoxides. Tetrahedron Letters. 36(1). 15–18. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frank Bennett Breakdown of academic impact, for papers by Hariprasad Vankayalapati Breakdown of academic impact, for papers by Gary E. Schiltz Breakdown of academic impact, for papers by David M. Ryckman Breakdown of academic impact, for papers by Kiyohiro Nishikawa Breakdown of academic impact, for papers by Edward H. Walker Breakdown of academic impact, for papers by Sun‐Young Han Breakdown of academic impact, for papers by Kanami Yamazaki Breakdown of academic impact, for papers by Giovanni Di Maira Breakdown of academic impact, for papers by Vered Klinghofer
Rankless by CCL
2026